Monthly Archives: August 2020

Introducing the “Optec Hydroxyl” Portable UVC Sterilization & Disinfection Device for in Car Use While Driving

CARLSBAD, CA / ACCESSWIRE / August 12, 2020 / OPTEC International Inc., (OTC PINK:OPTI) Today announced a massive breakthrough in the Pandemic prevention fight for UVC sterilization in an environment that has remained without a solution for the majority of Americans, their vehicles. Until Now. OPTEC's introduction of the totally safe certified OPTEC HYDROXYL portable disinfecting and sterilization device cleans the air inside the vehicle while simultaneously sanitizing and disinfecting using active OH radicals and deep penetration sterilization. The OPTEC Hydroxyl Air Sterilizer uses OH radicals to transform virus proteins, therefore decomposing bacteria and viruses. It is a safe and fast sterilizer for airborne infection for surface and material sterilization. It also removes dust and particles while deodorizing the areas to purify the air for better breathing conditions. Certified SGS test report results show 99.99% effective killing of bacteria, germs, organic pollutants and viruses.

The OPTEC Hydroxyl sterilizer can be a major requirement for the larger private transportation organizations, including Lyft, Uber, Taxi and personal livery companies, for rapid constant non-toxic sterilization of frequently used vehicles, now being mandated in most states for disinfection and sterilization for passenger safety after each ride.

OPTEC is a market leader in the development and distribution of (Ultra-Violet) UV-C & UV Germicidal Non-Toxic Sanitization and Disinfection using Chemical Free technologies and products. OPTEC is significantly helping in changing the Germicidal Sterilization & Disinfecting environment using UV-C Light and UV Products. Ultra-Violet light is now the Worlds most advanced solution for Killing Bacteria, Mites & Parasites whilst simultaneously de-activating 99% of Virus's in a non-chemical environment. The Company previously announced the introduction of a safer way to Re-Open in Person Schools across the country using a suite of OPTEC products as an alternative to distance learning options mandated in many states. Rd viruses. It is a safe and f

Additional Information Links Relating to Ultra-Violet Technology.

https://www.iheart.com/content/2020-07-29-jetblue-testing-ultraviolet-cleaning-robot-to-disinfect-planes/ https://www.dailymail.co.uk/health/article-8237137/Columbia-scientist-says-special-type-ultraviolet-light-secret-killing-coronavirus.html

https://www.cbsnews.com/news/new-york-city-subway-ultraviolet-light-coronavirus-mta/

https://www.ny1.com/nyc/all-boroughs/news/2020/05/19/mta-invests–1-million-in-uv-light-machines-to-clean-subways

https://abcnews.go.com/US/ultraviolet-light-zap-coronavirus-york-city-subways-buses/story?id=70770382

Safe Harbor Statement: Safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as Opti, OPTEC or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. OPTEC International Inc.

OPTEC UVC Website: www.optecuvc.com

OPTEC International, Inc. Contact: info@optecintl.com Call Center. 877- 955-8787

SOURCE: Optec International, Inc.

ReleaseID: 601271

Gold Terra Grants Options

VANCOUVER, BC / ACCESSWIRE / August 12, 2020 / Gold Terra Resource Corp. (TSX-V:YGT) (Frankfurt:TX0) (OTC PINK:TRXXF) ("Gold Terra" or the "Company) announces the grant of incentive stock options under the Company's stock option plan to its new director, employees and consultants to purchase up to an aggregate of 1,125,000 treasury shares. The options are exercisable at a price of $0.435 per share for a period of 5 years and are subject to the policies of the TSX Venture Exchange and the Company's stock option plan.

About Gold Terra's Yellowknife City Gold Project

The Yellowknife City Gold ("YCG") project encompasses 790 sq. km of contiguous land immediately north, south and east of the City of Yellowknife in the Northwest Territories. Through a series of acquisitions, Gold Terra controls one of the six major high-grade gold camps in Canada. Being within 10 kilometres of the City of Yellowknife, the YCG is close to vital infrastructure, including all-season roads, air transportation, service providers, hydro-electric power and skilled tradespeople.

The YCG lies on the prolific Yellowknife greenstone belt, covering nearly 70 kilometres of strike length along the main mineralized shear system that host the former-producing high-grade Con and Giant gold mines. The Company's exploration programs have successfully identified significant zones of gold mineralization and multiple targets that remain to be tested which reinforces the Company's objective of re-establishing Yellowknife as one of the premier gold mining districts in Canada.

Visit our website at www.goldterracorp.com.

For more information, please contact:

David Suda, President and CEO
Phone: 604-928-3101 | Toll-Free: 1-855-737-2684
dsuda@goldterracorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Gold Terra Resource Corp

ReleaseID: 601321

Predictmedix Inc. Announces Deployment of Impairment Screening Along with Covid-19 Symptom Screening Technology at Indian Oil Corporation LTD

TORONTO, ON / ACCESSWIRE / August 12, 2020 / Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) ("Predictmedix" or the "Company") is pleased to announce that it will be deploying its COVID-19 screening technology along with alcohol and impairment screening technology at Indian Oil Corporation Ltd (NSE:IOC.NS), ("IOCL") an Indian Public Sector Undertaking FORTUNE 500 company.

Predictmedix COVID-19 screening technology is designed to mass screen for symptomatic individuals to help reduce the risk of transmission in places which have a large movement of people. At the same time, impairment remains to be a massive health and safety issue at the workplace and Predictmedix impairment detection technology is designed to identify alcohol and cannabis impairment. The two Predictmedix technologies will be deployed at Indian Oil Bhawan, New Delhi. The deployment is expected to begin within the next 3-4 weeks.

"The deployment of our COVID-19 screening and impairment technology at IOCL which is a fortune 500 company marks our entry into the Oil & Gas sector which is one of the largest industrial sectors and it further highlights the market need for the suite of technologies developed by Predictmedix", said Dr. Kushwah, COO of Predictmedix.

Key appointments for business development:

Predictmedix is also pleased to appoint Kiran Kumari to the advisory board to assist with business development in Asia Pacific. Kiran is a senior Oil and gas executive and has assisted some of the largest multinational conglomerates with business development in Asia.

Technology development – US patent application:

Predictmedix is pleased to announce that it has filed a patent application, 63058567 – Utilizing healthcare providers network effect to increase compliance for better health outcomes, with the United States Patent and Trademark Office (USPTO) on July 30, 2020. The patent further enhances the features offered by Predictmedix telehealth/telemedicine and remote patient monitoring platform.

The present invention provides a novel method and system of management of rewards for care provider network for assisting in improved health of the patient and for compliance to a treatment protocol. The patent covers a partner reward management system and method for care partners/care providers to collectively contribute to improved health of the patient and accordingly rewarding the care providers and other wellness partners.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time."

About Indian Oil Corporation Ltd (IOCL):

Indian Oil Corporation Limited (IOCL), commonly known as Indian Oil is an Indian government-owned oil and gas company headquartered in New Delhi. It is ranked 1st in Fortune India 500 list for year 2016 and 117th in Fortune Global 500 list of world's largest companies in the year 2019. It is India's largest downstream oil company, with a workforce of more than 33,000 employees, with 2019 revenue of $85 billion USD.

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence ("AI") company developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious diseases such as influenza and coronaviruses (COVID-19). Our current partners along with advisory board members have played a key role in gathering data pertaining to COVID-19, which has allowed us to develop a predictive mass screening tool for COVID-19. The technology is for mass screening and is to be used to predict and identify individuals who have the highest likelihood of being infected with COVID-19.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease. To find out more visit us at www.predictmedix.com

For further information, please contact:

Dr. Rahul Kushwah, Chief Operating Officer
Tel: 647 889-6916
Email: rahul@predictmedix.com

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

SOURCE: PredictMedix Inc.

ReleaseID: 601273

ClickStream Adds Additional WinQuik(TM) Beta Test at 8:00 PM ET on Thursday, August 13th

Due To Overwhelmingly Strong Registration For The Gaming App And Digital Platform That Lets Players Compete For Cash And Prizes, Company Adds Another Timeslot

LOS ANGELES, CA / ACCESSWIRE / August 12, 2020 / Clickstream Corp (OTC PINK:CLIS) announced that its' synchronized digital app based live gaming platform will commence two beta tests for a select audience on August 13th at 8PM ET and 9PM ET.

To be eligible to participate, Clickstream has set up a sign-up page on WinQuik.com. The initial game will feature questions from all of WinQuik's hosts including NFL Network host and former NFL player Brian Baldinger, Fox Sports Amber Theoharis, NFL quarterback Joshua Dobbs, survival expert and retired US Army Green Beret Mykel Hawke, former ESPN host Howie Schwab, and celebrity chef Jordan Andino.

Frank Magliochetti, CEO of Clickstream, enthuses, "The response to the WinQuik Beta Test has been so incredible that we wanted to make sure as many people, on both coasts, could participate. We believe people will enjoy WinQuik and we're anxious to finally show it off."

ABOUT CLICKSTREAM CORPORATION
ClickStream's business operations are focused on the development and implementation of WinQuikTM, a free to play synchronized mobile app and digital gaming platform. The platform is designed to enable WinQuikTM users to have fun, interact and compete against each other in order to win real money and prizes. WinQuikTM is currently in post-production with shows featuring Joshua Dobbs, Jordan Andino, Brian Baldinger, Howie Schwab, Amber Theoharis, and Mykel Hawke. Subject matter includes sports, survival, food/culinary, the Bible and outer space. Game are set up dynamically with multiple non-live game shows throughout the day and once-a-day live game show. As a free-mium platform, ClickStream is in the process of monetizing the platform with corporate sponsors and advertisers. For more information please visit Clickstream's websites at www.clickstream.technology or www.WinQuik.com as well as on Twitter at @ClickstreamC and @WinQuikApp.

SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR MORE INFORMATION, PLEASE CONTACT:
Adam Handelsman
SpecOps Communications
adam@specopscomm.com
O: (512) 363-0594
C: (646) 413-9401

SOURCE: ClickStream Corporation

ReleaseID: 601265

Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors

HARRISON, NY / ACCESSWIRE / August 12, 2020 / Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat oncology indications, today announced dose administration for the first patient in a Phase 1/2, open-label, dose escalation and expansion study of single agent ST101, a peptide therapy being evaluated for the treatment of adults with unresectable and metastatic solid tumors who are not eligible for other therapies or have progressed on prior therapies.

"The initiation of this study represents a significant milestone for Sapience, as it marks the first program from our portfolio of peptide therapies to enter the clinic," said Alice Bexon, M.D., Chief Medical Officer of Sapience Therapeutics. "The ST101 program highlights Sapience's therapeutic approach of using peptides to target intracellular protein-protein interactions, which are often referred to as 'Undruggable Targets'. Through this study, we anticipate generating a wealth of clinical data to guide our future development plans for this first-in-class antagonist of C/EBPβ."

Nehal Lakhani, M.D., Ph.D., Director of Clinical Research at START Midwest (South Texas Accelerated Research), and a clinical investigator on the study added, "We are eager to explore the profile of ST101 and to investigate the role of C/EBPβ inhibition for the treatment of advanced solid tumors. We are always looking for opportunities to accelerate the development of new treatments to improve patients' lives and give them hope against cancer, and ST101 holds that potential."

The Phase 1/2 trial will enroll patients at several leading clinical centers in the US and UK. The trial will start with a dose escalation phase to assess the safety and tolerability of ST101, followed by an expansion phase to evaluate preliminary efficacy in patients with glioblastoma, locally advanced/metastatic breast cancer, castration-resistant prostate cancer and melanoma. Please refer to www.clinicaltrials.gov for additional information (NCT 04478279).

About ST101

ST101 is a peptide antagonist of the transcription factor C/EBPβ, which is typically expressed and active in stem cells or early progenitor cells but not in most mature or differentiated cells. Certain cancers activate C/EBPβ, which results in the expression of genes with roles in cell proliferation, differentiation, and the cell cycle. Disruption of this transcription factor with ST101 results in targeted killing of cancer cells, as normal cells do not rely on C/EBPβ driven transcription for survival.

About Sapience Therapeutics

Sapience Therapeutics, Inc., is a privately held, clinical stage biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein-protein interactions, Sapience's molecules hold potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience's product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Contacts

Sapience Therapeutics, Inc.:
Barry Kappel, Ph.D., M.B.A.
President and Chief Executive Officer
info@sapiencetherapeutics.com

SOURCE: Sapience Therapeutics, Inc.

ReleaseID: 601209

Global Industrial Launches Home Office | Home School – We Can Supply That(R) Initiative

Provides practical solutions and recommendations as adults and children adjust to remote work and learning spaces

PORT WASHINGTON, NY / ACCESSWIRE / August 12, 2020 / Global Industrial, a value-added national distributor of industrial products and MRO supplies, and a Systemax Inc. (NYSE:SYX) company, today announced that it has launched its Home Office | Home School initiative to help customers optimize their home based work and learning environments. While many people established short term work and classroom spaces, those initial areas are being re-evaluated and adjusted to ensure a more optimized and comfortable environment. Global Industrial is assisting in the transition of these critical home spaces, by offering customers practical advice to create a unique and comfortable environment, that enhances productivity and efficiency.

What began as temporary home learning spaces for children has transitioned to permanence in many states. This creates the need for a separate learning environment that will allow families to simplify and streamline school work at home. Helping to replicate a classroom environment can make it easier for children to learn and parents to stay organized. A dedicated learning space with the proper desk and a chair fit for learning, are just some of the items needed to create a sound and productive environment. Additional ideas and solutions can be found in Global Industrial's Home School Guide.

The worldwide pandemic has forced many businesses into a remote workforce transition. This has created the need for permanent home office space that enables productivity and efficiency. Replicating the office work space by defining a home office headquarters, with proper desk ergonomics and efficient organization, creates a successful home office experience. Planning and rethinking your home office begins with the Global Industrial Home Office Guide.

"From the start of this pandemic Global Industrial has taken a customer centric approach to deliver solutions that help our customers succeed and support the rebound of their businesses," said Chief Marking officer Klaus Werner. "From personal protection equipment, and safety supplies, to our ‘From Bus Stop to Last Bell' school guide we are helping customers take a practical and step by step look at their current environments. We are proud to launch the Home Office | Home School initiative, which expands our business and industrial solutions to the home."

For more information on how Global Industrial is helping businesses rebound, including its From Bus Stop to Last Bell school guide and room by room approach visit: Restore, Return, Rebound – We Can Supply That®.

About Global Industrial
Global Industrial (www.globalindustrial.com) is a subsidiary of Systemax Inc. (NYSE:SYX). Global offers over 1.7 million industrial, material handling and business products for Fortune 1000 companies, small businesses, institutions and government agencies.

About Systemax Inc.
Systemax Inc. (www.systemax.com), through its operating subsidiaries, is a value added distributor of industrial products in North America going to market through a system of branded e-Commerce websites and relationship marketers. The primary brand is Global Industrial.

Forward-Looking Statement
This press release contains forward looking statements within the meaning of that term in the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Additional written or oral forward-looking statements may be made by Systemax Inc, the parent company of Global Industrial, from time to time in filings with the Securities and Exchange Commission or otherwise. Any such statements that are not historical facts are forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's estimates, assumptions and projections and are not guarantees of future performance.

Investor/Media Contact:
Mike Smargiassi/ Ryan Golden
The Plunkett Group
212-739-6740
mike@theplunkettgroup.com ryan@theplunkettgroup.com

SOURCE: Systemax via EQS Newswire

ReleaseID: 601218

Quad M Solutions is Entering into Letter of Intent to Acquire iCan Benefit Group

Huge Cross-Selling Opportunity With Nearly 1 Million Insurance Policies Sold by iCan Benefit Group

EDGEWATER, NJ / ACCESSWIRE / August 12, 2020 / Quad M Solutions, Inc. (OTC PINK:MMMM) ("Quad M" or the "Company"), a public holding company that offers staffing services and employee benefits such as health plans, HR-human resources, and payroll services, to small and mid-sized group employers. It has four subsidiaries, NuAxess 2, Inc., PrimeAxess, Inc., OpenAxess, Inc. and PrimeAxess 2, LLC. Quad M is pleased to announce it is entering into a letter of intent ("LOI") to acquire iCan Benefit Group ("iCan"), a provider of improved individual, employer, and employee benefits and affordable insurance and benefit options.

The NuAxess 2, Inc. subsidiary gives employer members access to timely and reliable healthcare information through interactive member engagement programs, enabling them to manage and control their health benefit decisions along with their chosen doctors. NuAxess ‘Smart' Plans don't require coinsurance, medical copays, and costs are transparent to all, and plans permit unrestricted access to any doctor or hospital. Furthermore, the NuAxess Smart Plan has a unique dual deductible feature that includes a Health Savings Account. The Plan is supported by an extensive technology platform of strategic vendor programs operating under a single source administration. The technology and these programs are available 24/7/365 to assist members in making healthcare-related decisions.

The proposed acquisition consideration is for common stock shares in Quad M Solutions, Inc. (OTC PINK:MMMM).

Pat Dileo, Quad M Solutions' Chief Executive Officer, commented, "iCan has created a tremendous technology and management team platform that assists individuals and small employers with information and tools to make smarter decisions in the complicated world of insurance and benefits, and at affordable prices. They expertly simplify the process for members of obtaining needed health and benefit coverage through a system of hands on support and technology. We believe it makes a great strategic fit that bolsters our strategy of providing our proprietary Nuaxess Smart Plan with its HSA, and monetizes the emerging gig economy workers that will drive tremendous profitability."

Mr. Stephen Tucker, iCan Benefit Group's Chief Executive Officer, stated, "Quad M Solutions is ideally situated for moving the small group employer market and gig economy into the self-insured world of employee benefits. We believe our platform and audience will combine well with Quad M and its Nuaxess strategy, as having a self-insured major medical plan to cross-sell that will accelerate future growth of sales and revenue. We look forward to integrating our solutions and experience and we are enthusiastic about the cross-selling opportunities. iCan can bring the potential to monetize this vast community we have built and assembled with 900,000 insurance policies initiated since inception and fast-approaching one million."

Mr. Tucker, continued, "From our early TV direct-to-consumer days, we are poised to dramatically increase our market share with quality products and at lower prices. We launched a Telemedicine platform in 2006 long before the pandemic of 2020, brought advocacy and bundled services in 2007, delivered the first access to Humana"s discounted Rx rates, brought guaranteed coverage benefits and covered preexisting conditions ahead of the industry. We have designed our system as a single source insurance advisory service which is now in huge demand by the American insurance consumer, especially millennials and those businesses that make up the growing gig economy. With approximately 900,000 new policies since inception, we are finally poised to connect consumers with our combined products, major insurance carriers, and exacting services that today's consumers demand and expect. Automated requoting, up to the minute second pricing options, and utilizing predictive analytics from the use of our collected real-time data to accurately quote plan costs to assist customers decision making which they have been asking for the last two decades."

Mr. Tucker, concluded, "Reference based pricing, streamlined coverages, tele-health services, tele-mental and behavioral health, dental and vision have come full circle. By combining Auto, Home, Life, Medical and catastrophic illness protection we can finally lower rates and increase benefits. Retail giants' growth over the decades required logistics that were improved through technology advances, e.g., machine learning, voice recognition, access to real time data, informatics, etc., that when used properly disrupted the status quo players and benefitted the consumers experience. Key to the use of member data is strict confidentiality with full HIPAA compliance. iCan will create access to the best services, lower costs and all in one place providing more quality benefits and removing many of the unwanted middlemen costs. America deserves better healthcare benefits and with Quad M Solutions, iCan is ready to scale its delivery and solutions to a previously struggling marketplace of America's essential workers."

About iCan Benefit Group
Founded in 2004, iCan Benefit Group is a dynamic, customer-centric family of companies successfully serving Americans across the country with access to comprehensive, affordable insurance solutions. As more individuals than ever enter the market looking for individual health insurance options, iCan's Single Insurance Advisor model is the answer for so many, and is uniquely positioned to outperform and grow. iCan Benefit Group has enrolled over 900,000 policies and benefit products since inception across the health, life and property and casualty insurance verticals.

iCan's holistic approach to benefit plan management includes product design and implementation, digital media and marketing, sales and distribution, billing administration, fulfillment, elite service and member advocacy. iCan is poised to offer personalized, preferred and recommended interactions across the customer journey through continued innovation in AI, BI and predictive analytics. iCan focuses on increasing access and utilization of wellness-based initiatives through its full-scale ability to design, implement, market, sell and service custom tailored insurance products for the individual consumer. iCan can deliver the products, carriers, and services our growing customer base needs and demands.

About Quad M Solutions, Inc.
Quad M Solutions, Inc., is a public holding company that offers self-funded health plans, staffing services, HR-human resources, payroll services, retirement, supplemental and workers compensation insurance to small and mid-sized group employers with 1-500 employees, and to the exploding essential worker "Gig Economy," a labor market that is characterized by the prevalence of short-term contracts or freelance work, not permanent jobs. The company's four subsidiaries, NuAxess 2, Inc., PrimeAxess, Inc., OpenAxess, Inc. and PrimeAxess 2, LLC are important in conveying who we are and what we do.

We strive to provide those employers and individuals the right tools to be able to manage and control all the facets in their healthcare experience and their eventual health outcomes. Prevention, wellness, and cures have become part of our corporate mission to individuals who want to manage and control their short and long-term healthcare needs.

Our self-insured programs are consumer-driven and technology-leveraged and, by itself, self-insurance is affordable, transparent and responsive to the healthcare and retirement needs of employees who are looking for higher quality benefits, integrated health information and better medical provider access and outcomes.

For additional information, please visit: QuadMSolutions.com and NuAxess.com.

Forward-Looking Statements
The statements contained herein that are not historical facts are forward-looking statements within the meaning of the federal securities laws (Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). You can identify such forward-looking statements by the words "expects," "intends," "plans," "projects," "believes," "estimates," "likely," "possibly," "probably," "goal," "opportunity," "objective," "target," "assume," "outlook," "guidance," "predicts," "appears," "indicator" and similar expressions. Forward-looking statements involve a number of risks and uncertainties. In the normal course of business, Quad M Solutions, in an effort to help keep our stockholders and the public informed about our operations, may from time to time issue such forward-looking statements, either orally or in writing. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of such plans or strategies, or projections involving anticipated revenues, earnings, profits, pricing, operating expenses or other aspects of operating results. We base the forward-looking statements on our expectations, estimates, and projections at the time such statements are made. These statements are not guarantees of future performance and involve risks and uncertainties that we cannot predict. In addition, we have based many of these forward-looking statements on assumptions about future events that may prove to be inaccurate. The actual results of the future events described in such forward-looking statements could differ materially from those stated in such forward-looking statements.

Corporate Contact:
Pat Dileo
CEO, Chairman, Quad M Solutions, Inc.
P:732-423-5520
P:844-NuAxess

Investors:
IR@QuadMsolutions.com

SOURCE: Quad M Solutions, Inc.

ReleaseID: 601287

GOIP Announces Asset Purchase Agreement to Acquire FedEx Ground and Home Routes in the New York City Area

NEW YORK, NY / ACCESSWIRE / August 12, 2020 / GoIP Global Inc (OTC PINK:GOIG) announced today, the signing of an asset purchase agreement to acquire substantially all of the assets of a privately-held transportation company that operates FedEx home and ground routes in the NYC area, this follows the LOI that was announced in a press release on June 1, 2020. The acquisition is subject to approval by FedEx; as well as the acquisition of a second FedEx route that the Company has signed a letter of intent to acquire. As previously stated, the purchase price will be paid in cash and will not be dilutive to shareholders. The Company expects the acquisition to be immediately accretive.

The acquisition is part of GoIP's (to be renamed TransWorld Holdings) strategy to build a transportation division that is expected to provide strong and consistent cash-flow. The Company sees FedEx routes as opportunistic in today's changing "on demand," e-commerce economy. It is the Company's intention to acquire additional FedEx routes as it builds its transportation unit.

TransWorld's Board see tremendous opportunities in growing further into the e-commerce and "on-demand" economy. TransWorld's primary focus is to bring value to its shareholders.

About FedEx Routes
Many FedEx delivery routes are not actually owned by FedEx, but rather by small independent businesses. These businesses maintain a contract with FedEx which outlines the services to be provided by the contractor, standards required by FedEx, and the area the contractor is assigned (the zip code/route). FedEx pays these contractors on a weekly basis. These routes are divided between Line Haul, Ground and Home delivery services.

About GoIP Global/ TransWorld Holdings Inc.
TransWorld's mission is to operate as a profitable holding company operating in a number of business segments, initially including transportation, simple technology services, consumer goods and active investments. TransWorld's primary focus is to bring value to its shareholders by bringing last mile solutions in the ecommerce world. TransWorld is in the process of changing its name to TransWorld Holdings Inc. and will apply for a new symbol. To learn more, please visit www.transworldenterprises.com.

Safe Harbor Statement Information in this news release may contain statements about future expectations, plans, prospects or performance of GoIP Global, Inc. that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. GoIP Global, Inc. cautions you that any forward-looking information provided by or on behalf of GoIP Global, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. GoIP Global, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond GoIP Global, Inc.'s control. In addition to those discussed in GoIP Global, Inc.'s press releases, public filings, and statements by GoIP Global, Inc.'s management, including, but not limited to, GoIP Global, Inc.'s estimate of the sufficiency of its existing capital resources, GoIP Global, Inc.'s ability to raise additional capital to fund future operations, GoIP Global, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match GoIP Global, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. GoIP Global, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT:
GoIP Global Inc
ko@transworldenterprises.com
1-917-268-0660

SOURCE: GoIP Global Inc

ReleaseID: 601261

ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19

ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as Q4 2020

WESTMINSTER, CO / ACCESSWIRE / August 12, 2020 / ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has completed a pre-Investigational New Drug (IND) consultation with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP). The FDA provided feedback for ARCA's clinical development plans for evaluating AB201 as a potential treatment for patients with severe COVID-19. With this feedback, ARCA anticipates submitting its IND application in September 2020 in preparation for initiating a Phase 2B clinical trial as early as the fourth quarter of this year.

A pre-IND meeting provides an opportunity for an open communication between the sponsor and the FDA to discuss the IND development plan and to obtain the FDA's guidance for clinical trials for the sponsor's new drug candidate. The FDA has created CTAP as a special emergency program for possible coronavirus therapies which is designed to use every available method to move new treatments to patients as quickly as possible, while evaluating safety and effectiveness.

Dr. Michael Bristow, ARCA's President and Chief Executive Officer, commented, "Receiving the FDA's guidance is an important step in developing and executing our clinical development program for AB201. With what we believe to be a strong scientific rationale, safety data from prior human clinical trials in over 700 patients, and a well-defined regulatory pathway, we believe AB201 has potential as a therapeutic treatment for COVID-19. AB201's differentiated mechanism of action may also allow for use in combination with other COVID-19 therapeutics and provide a potential treatment for those patients who cannot take vaccines or for whom vaccines are not effective."

About AB201 (rNAPc2)
AB201 is a small recombinant protein being developed as a potential treatment for RNA virus- associated disease, initially focusing on COVID-19. AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. AB201 has previously undergone Phase 1 and Phase 2 testing in more than 700 patients, including as an anti-thrombotic agent in the setting of acute myocardial infarction (MI), where it showed efficacy in inhibiting the TF pathway and was well tolerated at therapeutic doses. Recent research suggests that the disease syndrome caused by coronavirus may have much in common with other severe infections in which the infection process causes inappropriate activation of the coagulation system, resulting in serious complications. Recent mechanistic discoveries, as well as prior data from studies in non-human primates (NHPs) given lethal doses of Ebola or Marburg filoviruses demonstrating morbidity and mortality reductions, decreases in inflammatory biomarkers and reduction in viral load, indicate that AB201 may have important antiviral and anti-inflammatory activity in addition to its anticoagulant effects. The Company believes that collectively these observations provide a strong rationale for investigating AB201 as a treatment for COVID-19 and other RNA virus associated diseases.

About ARCA biopharma
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing AB201 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted atrial fibrillation (AF) prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding potential future development plans for AB201 and Gencaro, the expected features and characteristics of AB201 and Gencaro, including the potential for genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat atrial fibrillation, AB201's potential to treat COVID-19 or any other RNA virus associated disease, future treatment options for patients with COVID-19, and the potential for Gencaro to be the first genetically targeted AF prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA's financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of AB201 or Gencaro or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA's filings with the Securities and Exchange Commission, including without limitation ARCA's annual report on Form 10-K for the year ended December 31, 2019, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com

SOURCE: ARCA biopharma, Inc.

ReleaseID: 601279

Leafbuyer Technologies, Inc. Announces Record Sales Month for Dispensary Vertical

Cannabis Technology Company Records 64% Sales Growth During Pandemic

DENVER, CO / ACCESSWIRE / August 12, 2020 / Leafbuyer Technologies, Inc. ("Leafbuyer" or "the Company") (OTCQB:LBUY), a leading cannabis technology company, announced today that its monthly cash sales rose 64% in the month ending July 31, 2020. The increase reflects dispensary cash sales booked in the month versus the same month of the previous year.

Leafbuyer's development of new technologies, sales and marketing initiatives, and point of sale integrations account for the year-over-year success.

"We made a strong pivot at the start of the pandemic, and it is paying off. Exceeding our sales goals is a major focus of the organization," said Kurt Rossner, CEO of Leafbuyer. "By creating the highest quality, technology-driven products and using these innovations to secure new clients, we look to continue this momentum and achieve our goal of profitability in the very near future."

The Company has made significant progress in recent months by developing advanced Leafbuyer Loyalty "wallet" features, bolstering its texting platform, integrating with major POS companies, and launching new marketing channels designed to enhance Leafbuyer's value proposition and attract more customers.

"I am extremely excited about our direction and the advancements the Leafbuyer team has made over the last year," continued Rossner. "We will continue to execute our strategic initiatives and position Leafbuyer Technologies as a dominant player in the cannabis industry."

To learn more about Leafbuyer, visit Tech.Leafbuyer.com.

About Leafbuyer Technologies, Inc.
Leafbuyer Technologies is one of the most comprehensive technology and communication software providers for the cannabis industry. Leafbuyer.com is an all-inclusive online resource for cannabis deals and information. Leafbuyer works alongside businesses to showcase their unique products and build a network of loyal patrons. Leafbuyer's national network of cannabis deals and information reaches millions of consumers every month. Leafbuyer is the official cannabis deals platform of Dope Media, Sensi Magazine, and Voice Media Group. Learn more at Tech.Leafbuyer.com.

CONTACT:
Leafbuyer Technologies, Inc.
Andre Leonard, +720-432-5593
aleonard@leafbuyer.com

SOURCE: Leafbuyer Technologies, Inc.

ReleaseID: 601269